The pharmacology of GR203040, a novel, potent and selective non‐peptide tachykinin NK1 receptor antagonist

No abstract is available for this paper.

• Publication year

  1995

• Venue

  British Journal of Pharmacology

• Publication date

  1995-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1476-5381.1995.tb15117.xPMID 8719789PMCID PMC1909174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Substance P: Localization, concentration and release in cerebral arteries, choroid plexus and dura mater

  2004cited by this paper
• NK1 and CGRP receptor-mediated dilatation of the carotid arterial bed of the anaesthetized rabbit.

  1996cited by this paper
• GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors.

  1995cited by this paper
• The broad‐spectrum anti‐emetic activity of the novel non‐peptide tachykinin NK1 receptor antagonist GR203040

  1995cited by this paper
• Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in Dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats.

  1995cited by this paper
• Recent developments in tachykinin NK1 receptor antagonists: prospects for the treatment of migraine headache.

  1995cited by this paper
• Discovery of an orally bioavailable NK1 receptor antagonist, (2S,3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity.

  1995cited by this paper
• Cardiovascular effects of CP-96,345, a non-peptide blocker of tachykinin NK1 receptors.

  1994cited by this paper
• Non‐specific actions of the non‐peptide tachykinin receptor antagonists, CP‐96, 345, RP 67580 and SR 48968, on neurotransmission

  1994cited by this paper
• Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor.

  1993cited by this paper
• The non‐peptide neurokinin1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats

  1993cited by this paper
• Tachykinin receptors and tachykinin receptor antagonists.

  1993cited by this paper
• Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists.

  1993cited by this paper
• Neurokinin‐induced changes in pial artery diameter in the anaesthetized guinea‐pig

  1993cited by this paper
• Inhibition of neurogenic inflammation in the meninges by a non-peptide NK1 receptor antagonist, RP 67580.

  1993cited by this paper
• Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets.

  1993cited by this paper
• The inhibition of neurogenic inflammation.

  1993cited by this paper
• Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists

  1993cited by this paper
• Block of voltage‐dependent sodium currents by the substance P receptor antagonist (±)‐CP‐96,345 in neurones cultured from rat cortex

  1993cited by this paper
• Characterization of a Human NK1 Tachykinin Receptor in the Astrocytoma Cell Line U 373 MG

  1993cited by this paper
• The interaction of the NK1 receptor antagonist CP‐96,345 with L‐type calcium channels and its functional consequences

  1993cited by this paper
• In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist.

  1993cited by this paper
• Biochemical characterization and solubilization of human NK2 receptor expressed in Chinese hamster ovary cells.

  1993cited by this paper
• The substance P receptor antagonist CP-96,345 interacts with Ca2+ channels.

  1992cited by this paper
• Rapid communicationThe substance P receptor antagonist CP-96,345 interacts with Ca2+ channels

  1992cited by this paper
• Regulation of G418 selection efficiency by cell-cell interaction in transfection

  1992cited by this paper
• Pharmacology of neurokinin receptors

  1991cited by this paper
• Investigation into species variants in tachykinin NK1 receptors by use of the non‐peptide antagonist, CP‐96,345

  1991cited by this paper
• A potent nonpeptide antagonist of the substance P (NK1) receptor.

  1991cited by this paper
• Pharmacological properties of a potent and selective nonpeptide substance P antagonist.

  1991cited by this paper
• Species differences in affinities of non-peptide antagonists for substance P receptors.

  1991cited by this paper
• The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater

  1990cited by this paper
• Pharmacological analysis of [3H]‐senktide binding to NK3 tachykinin receptors in guinea‐pig ileum longitudinal muscle‐myenteric plexus and cerebral cortex membranes

  1990cited by this paper
• Pain mechanisms underlying vascular headaches. Progress Report 1989.

  1989cited by this paper
• Calcium phosphate-mediated gene transfer: a highly efficient transfection system for stably transforming cells with plasmid DNA.

  1988cited by this paper
• Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system

  1988cited by this paper
• Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain

  1987cited by this paper
• Does substance P act as a pain transmitter

  1987cited by this paper
• Pharmacological characterization and autoradiographic localization of substance P receptors in guinea pig brain.

  1986cited by this paper
• Stereospecific receptors for substance P on cultured human IM-9 lymphoblasts.

  1984cited by this paper
• The classification of drugs and drug receptors in isolated tissues.

  1984cited by this paper
• Substance P.

  1983cited by this paper
• Substance P.

  1982cited by this paper
• Substance P: immunohistochemical localization and effect upon cat pial arteries in vitro and in situ.

  1981cited by this paper
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

  1976cited by this paper
• RECEPTORS FOR 5‐HYDROXYTRYPTAMINE AND NORADRENALINE IN RABBIT ISOLATED EAR ARTERY AND AORTA

  1976cited by this paper
• Proceedings: Receptors for 5-hydroxytryptamine and noradrenaline in rabbit aorta and central ear artery.

  1974cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper
• An unidentified depressor substance in certain tissue extracts

  1931cited by this paper

• Substance P and the trigeminovascular system: From preclinical mechanisms to human headache induction

  2025cites this paper
• Neurokinin‐1 receptor‐based bivalent drugs in pain management: The journey to nowhere?

  2019cites this paper
• Redox Mechanisms in Migraine: Novel Therapeutics and Dietary Interventions

  2017cites this paper
• Anti-Inflammatory Activity

  2016cites this paper
• Emetic and Antiemetic Activity

  2014cites this paper
• Effects on Blood Supply and on Arterial and Venous Tonus

  2014cites this paper
• Psychostimulants, antidepressants and neurokinin-1 receptor antagonists ('motor disinhibitors') have overlapping, but distinct, effects on monoamine transmission: the involvement of L-type Ca2+ channels and implications for the treatment of ADHD.

  2014cites this paper
• Positron emission tomography in CNS drug discovery and drug monitoring.

  2014cites this paper
• Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.

  2013cites this paper
• Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.

  2012cites this paper
• The biological basis of headache

  2011cites this paper
• Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.

  2011cites this paper
• Knowledge-based analysis of multi-potent G-protein coupled receptors ligands.

  2010cites this paper
• Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.

  2009cites this paper
• Pregabalin and gabapentin inhibit substance P‐induced NF‐κB activation in neuroblastoma and glioma cells

  2008cites this paper
• Tachykinins and their functions in the gastrointestinal tract

  2007cites this paper
• Kinetic gait and subjective analysis of the effects of a tachykinin receptor antagonist in dogs with sodium urate-induced synovitis.

  2007cites this paper
• Prevention of emesis from multiple-day and high-dose chemotherapy regimens.

  2007cites this paper
• Vertigo and Motion Sickness. Part II: Pharmacologic Treatment

  2006cites this paper
• Attenuation of the gerbil writhing response by μ-, κ- and δ-opioids, and NK-1, -2 and -3 receptor antagonists

  2004cites this paper
• PREDICT modeling and in‐silico screening for G‐protein coupled receptors

  2004cites this paper
• Role of Neurokinin-1 Receptor Antagonists in Chemotherapy-Induced Emesis: Summary of Clinical Trials

  2004cites this paper
• Inhibiting substance p pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists.

  2004cites this paper
• The Role of Tachykinins and the Tachykinin NK1 Receptor in Nausea and Emesis

  2004cites this paper
• Attenuation of the gerbil writhing response by mu-, kappa- and delta-opioids, and NK-1, -2 and -3 receptor antagonists.

  2004cites this paper
• The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.

  2004cites this paper
• Effects of antidepressant drugs and GR 205171, an neurokinin-1 (NK1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse.

  2003cites this paper
• Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets.

  2003cites this paper
• Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice.

  2003cites this paper
• NK1 Receptor Occupancy in the Monkey Brain Studied by [11C]GR205171

  2002cites this paper
• Analgesic, anti-inflammatory, and anti-pyretic activity1

  2002cites this paper
• SSR240600 [(R)-2-(1-{2-[4-{2-[3,5-Bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl}- 4-piperidinyl)-2-methylpropanamide], a Centrally Active Nonpeptide Antagonist of the Tachykinin Neurokinin-1 Receptor: I. Biochemical and Pharmacological Characterization

  2002cites this paper
• SSR240600 [(R)-2-(1-{2-[4-{2-[3,5-Bis(trifluoromethyl)phenyl]acetyl}-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl}-4-piperidinyl)-2-methylpropanamide], a Centrally Active Nonpeptide Antagonist of the Tachykinin Neurokinin 1 Receptor: II. Neurochemical and Behavioral Characterization

  2002cites this paper
• Mediators and their receptors involved in neurogenic inflammation

  2002cites this paper
• Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists.

  2002cites this paper
• Migraine: A Neuroinflammatory Disease?

  2002cites this paper
• Peptide-binding G protein-coupled receptors: new opportunities for drug design.

  2001cites this paper
• Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting

  2001cites this paper
• Pharmacological opportunities and pitfalls in the therapy of migraine

  2001cites this paper
• Substance P receptor antagonists in the therapy of migraine

  2001cites this paper
• Neurokinin(1) receptor antagonists as potential antidepressants.

  2001cites this paper
• Excitatory non-adrenergic-non-cholinergic neuropeptides: key players in asthma.

  2000cites this paper
• Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171--PET studies in rhesus monkey.

  2000cites this paper
• Modelling trigeminovascular pain in the unrestrained rat : an approach to a better understanding of migraine headache

  2000cites this paper
• Substance P

  2000cites this paper
• CHIRAL SEPARATION OF 4,4-DISUBSTITUTED PIPERIDINYL SUBSTANCE P ANTAGONISTS

  2000cites this paper
• The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets.

  2000cites this paper
• Inhibition of emesis by tachykinin NK1 receptor antagonists in Suncus murinus (house musk shrew).

  1999cites this paper
• Current animal models are not predictive for clinical asthma.

  1999cites this paper
• Antiemetics for Cancer Chemotherapy—Induced Nausea and Vomiting

  1999cites this paper
• Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis.

  1999cites this paper
• Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368.

  1999cites this paper
• Randomized P hase I I S tudy o f t he N eurokinin 1 Receptor A ntagonist C J-11,974 i n t he C ontrol of C isplatin-Induce d E mesis

  1999cites this paper
• Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology.

  1999cites this paper
• Effects of GR203040, an NK1 antagonist, on radiation- and cisplatin-induced tissue damage in the ferret.

  1998cites this paper
• Differential effects of neurokinin-1 receptor activation in subregions of the periaqueductal gray matter on conditional and unconditional fear behaviors in rats.

  1998cites this paper
• Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist.

  1998cites this paper
• Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist

  1998cites this paper
• Improved discriminatory properties between human and murine tachykinin NK1 receptors of MEN 10930: a new potent and competitive antagonist.

  1997cites this paper
• Analgesic, anti-inflammatory, and antipyretic activity

  1997cites this paper
• In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists.

  1997cites this paper
• The activity of GR205171, a potent non-peptide tachykinin NK1 receptor antagonist, in the trigeminovascular system.

  1997cites this paper
• Activity on the Gastrointestinal Tract

  1997cites this paper
• Neurokinin Receptor Antagonists

  1997cites this paper
• Tachykinins: Central and Peripheral Effects

  1997cites this paper
• The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation and cough.

  1997cites this paper
• An explanation for the increasing incidence of testis cancer: decreasing age at first full-term pregnancy.

  1997cites this paper
• The NK1 antagonist GR203040 inhibits cyclophosphamide-induced damage in the rat and ferret bladder.

  1997cites this paper
• Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin.

  1997cites this paper
• L-733,060, a novel tachykinin NK1 receptor antagonist; effects in [Ca2+]i mobilisation, cardiovascular and dural extravasation assays.

  1996cites this paper
• Tetrazole NK1 receptor antagonists: The identification of an exceptionally potent orally active antiemetic compound

  1996cites this paper
• GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity.

  1996cites this paper
• Tachykinins: receptor to effector.

  1996cites this paper
• Tachykinin receptor antagonists and cough.

  1996cites this paper
• 3-benzylamino-2-phenylpiperidines en tant qu'antagonistes de neurokinine

  1996cites this paper
• The action of the NK1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret

  1996cites this paper
• The broad‐spectrum anti‐emetic activity of the novel non‐peptide tachykinin NK1 receptor antagonist GR203040

  1995cites this paper